Clinical Trials Update: Aug. 23, 2007
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate whether an experimental drug known as CG5503 (tapentadol) extended release is safe and effective when used by people who have long-lasting or frequently recurring cancer-related pain. The study drug and study procedures will be provided at no cost. To qualify, you must be at least 18 and have chronic cancer-related pain. Additional criteria may apply.
The research site is in Englewood, N.J.
This study will compare the effectiveness of the study drug vs. a placebo to treat acne vulgaris. Study drug and procedures will be provided at no cost. To qualify, you must be at least 12 years old and have moderate-to-severe facial acne. You will not qualify if you are pregnant or breast-feeding, have facial sunburns, or have participated in any drug study within the last 30 days.
The research site is in New York City.
This study will assess the effectiveness and safety of an investigational product vs. capecitabine in people with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine. To participate, you must be 18 years or older with confirmed pancreatic cancer and have failed first-line gemcitabine therapy. Additional criteria may apply.
The research site is in Santa Maria, Calif.
Copyright 2007 Thomson CenterWatch. All rights reserved.
Copyright © 2007 ScoutNews, LLC. All rights reserved.